We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

107 hedge funds and large institutions have $1.94B invested in Zentalis Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 41 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

840% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 5

215% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 13

85% more capital invested

Capital invested by funds: $1.05B → $1.94B (+$889M)

62% more funds holding

Funds holding: 66 → 107 (+41)

11.65% more ownership

Funds ownership: 80.2% → 91.85% (+12%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
107
Holders Change
+41
Holders Change %
+62.12%
% of All Funds
1.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
47
Increased
41
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$146M
2
BlackRock
BlackRock
New York
+$59.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$54.7M
4
State Street
State Street
Massachusetts
+$32.9M
5
APM
Avidity Partners Management
Texas
+$10.4M

Top Sellers

1
Viking Global Investors
Viking Global Investors
Connecticut
-$64.6M
2
FCM
Farallon Capital Management
California
-$32.4M
3
SAM
Sectoral Asset Management
Quebec, Canada
-$18.2M
4
Citadel Advisors
Citadel Advisors
Florida
-$8.38M
5
MC
Mayo Clinic
Minnesota
-$3.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$316M +$146M +3,234,158 +113%
MCMC
2
Matrix Capital Management Company
New Hampshire
$199M – – –
Viking Global Investors
3
Viking Global Investors
Connecticut
$156M -$64.6M -1,432,000 -32%
TCM
4
Tybourne Capital Management
Hong Kong
$138M – – –
RG
5
Redmile Group
California
$126M -$722K -16,002 -0.7%
Vanguard Group
6
Vanguard Group
Pennsylvania
$122M +$54.7M +1,212,170 +107%
BlackRock
7
BlackRock
New York
$118M +$59.3M +1,315,141 +137%
Citadel Advisors
8
Citadel Advisors
Florida
$78.1M -$8.38M -185,764 -11%
Primecap Management
9
Primecap Management
California
$71.2M -$499K -11,060 -0.8%
APM
10
Avidity Partners Management
Texas
$59M +$10.4M +230,881 +26%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$56.8M -$541K -11,994 -1%
PA
12
Perceptive Advisors
New York
$54.5M – – –
State Street
13
State Street
Massachusetts
$46.3M +$32.9M +729,915 +452%
Capital World Investors
14
Capital World Investors
California
$44.1M +$8.39M +186,000 +28%
AllianceBernstein
15
AllianceBernstein
Tennessee
$43.3M +$2.87M +63,678 +8%
EAM
16
Eventide Asset Management
Massachusetts
$43.2M -$3.58M -79,416 -9%
Federated Hermes
17
Federated Hermes
Pennsylvania
$40.5M – – –
MC
18
Mayo Clinic
Minnesota
$18.8M -$3.62M -80,255 -18%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$17.2M +$6.78M +150,342 +83%
Franklin Resources
20
Franklin Resources
California
$17M +$6.86M +152,112 +87%
Northern Trust
21
Northern Trust
Illinois
$14.7M +$6.25M +138,550 +96%
Invesco
22
Invesco
Georgia
$14.3M +$134K +2,960 +1%
PCH
23
Polar Capital Holdings
United Kingdom
$11.7M +$10.1M +225,000 New
Goldman Sachs
24
Goldman Sachs
New York
$11.6M +$8.65M +191,812 +596%
SFM
25
Sphera Funds Management
Israel
$9.91M -$189K -4,200 -2%
1
2 3 4 5

ZNTL Hedge Fund Activity: Q4 2020 in Review

107 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2020, worth a combined $1.94B — up 85% from $1.05B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ZNTL positions and 5 closed out — a net gain of 42 holders — while 41 added to existing stakes and 13 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was Viking Global Investors, cutting an estimated $64.6M.

  • 107 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2020, up from 66 in Q3 2020.
  • Funds reported $1.94B of Zentalis Pharmaceuticals stock for Q4 2020, up 85% quarter-over-quarter.
  • 47 funds opened new Zentalis Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of +42 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2020 was Fidelity Investments, an estimated $146M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2020 was Viking Global Investors, an estimated $64.6M sold.

Based on aggregated 13F filings for Q4 2020.